Pilot study to evaluate the safety and effectiveness of etidronate treatment for arterial calcification due to deficiency of CD73 (ACDC)
Background: Arterial calcification due to deficiency of CD73 (ACDC; OMIM 211800) is a rare genetic disease resulting in calcium deposits in arteries and small joints causing claudication, resting pain, severe joint pain, and deformities. Currently, there are no standard treatments for ACDC. Our prev...
Gespeichert in:
| Veröffentlicht in: | Vascular medicine (London, England) England), 2024-06, Vol.29 (3), p.245-255 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 255 |
|---|---|
| container_issue | 3 |
| container_start_page | 245 |
| container_title | Vascular medicine (London, England) |
| container_volume | 29 |
| creator | Ferrante, Elisa A Cudrici, Cornelia D Rashidi, Mahmood Fu, Yi-Ping Huffstutler, Rebecca Carney, Katherine Chen, Marcus Y St Hilaire, Cynthia Smith, Kevin Bagheri, Hadi Katz, James D Ferreira, Carlos R Gahl, William A Boehm, Manfred Brofferio, Alessandra |
| description | Background:
Arterial calcification due to deficiency of CD73 (ACDC; OMIM 211800) is a rare genetic disease resulting in calcium deposits in arteries and small joints causing claudication, resting pain, severe joint pain, and deformities. Currently, there are no standard treatments for ACDC. Our previous work identified etidronate as a potential targeted ACDC treatment, using in vitro and in vivo disease models with patient-derived cells. In this study, we test the safety and effectiveness of etidronate in attenuating the progression of lower-extremity arterial calcification and vascular blood flow based on the computed tomography (CT) calcium score and ankle–brachial index (ABI).
Methods:
Seven adult patients with a confirmed genetic diagnosis of ACDC were enrolled in an open-label, nonrandomized, single-arm pilot study for etidronate treatment. They took etidronate daily for 14 days every 3 months and were examined at the NIH Clinical Center bi-annually for 3 years. They received a baseline evaluation as well as yearly follow up after treatment. Study visits included imaging studies, exercise tolerance tests with ABIs, clinical blood and urine testing, and full dental exams.
Results:
Etidronate treatment appeared to have slowed the progression of further vascular calcification in lower extremities as measured by CT but did not have an effect in reversing vascular and/or periarticular joint calcifications in our small ACDC cohort.
Conclusions:
Etidronate was found to be safe and well tolerated by our patients and, despite the small sample size, appeared to show an effect in slowing the progression of calcification in our ACDC patient cohort.
(ClinicalTrials.gov Identifier NCT01585402) |
| doi_str_mv | 10.1177/1358863X241235669 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11608424</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1358863X241235669</sage_id><sourcerecordid>3070033113</sourcerecordid><originalsourceid>FETCH-LOGICAL-c424t-e10d9481767a5ef2513f26ea38f03b05c21164ca47a2857b699f038ea0ad7d413</originalsourceid><addsrcrecordid>eNp1kc9u1DAQhy0EoqXwAFyQJS7lkOKJE9s5oSqlBakSHEDiFs0649ZVNi62s9K-AY-Nly3lnzjZ8nzz-Tcaxp6DOAHQ-jXI1hglv9QN1LJVqnvADqHRuhJS64flXurVDjhgT1K6EUJo1cFjdiBNqwwIfci-ffRTyDzlZdzyHDhtcFowE8_XxBM6yluO88jJObLZb2imlHhwnLIfY5h_oJEwr2nO3IXIMWaKHiducbLeeYvZh5mPC-38I5UXT7Pd7iT9mZb8-LQ_6189ZY8cTome3Z1H7PP520_9u-ryw8X7_vSysk3d5IpAjF1jQCuNLbm6BelqRSiNE3IlWlsDqMZio7E2rV6prisFQyhw1GMD8oi92Xtvl9WaRltiR5yG2-jXGLdDQD_8WZn99XAVNkPxClMyFMPxnSGGrwulPKx9sjRNOFNY0iCFBNUa1XYFffkXehOWOJf5CqWFkBJAFgr2lI0hpUjuPg2IYbfo4Z9Fl54Xv49x3_FzswU42QMJr-jXt_83fgezI7Fv</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3070033113</pqid></control><display><type>article</type><title>Pilot study to evaluate the safety and effectiveness of etidronate treatment for arterial calcification due to deficiency of CD73 (ACDC)</title><source>MEDLINE</source><source>SAGE Complete A-Z List</source><source>Alma/SFX Local Collection</source><creator>Ferrante, Elisa A ; Cudrici, Cornelia D ; Rashidi, Mahmood ; Fu, Yi-Ping ; Huffstutler, Rebecca ; Carney, Katherine ; Chen, Marcus Y ; St Hilaire, Cynthia ; Smith, Kevin ; Bagheri, Hadi ; Katz, James D ; Ferreira, Carlos R ; Gahl, William A ; Boehm, Manfred ; Brofferio, Alessandra</creator><creatorcontrib>Ferrante, Elisa A ; Cudrici, Cornelia D ; Rashidi, Mahmood ; Fu, Yi-Ping ; Huffstutler, Rebecca ; Carney, Katherine ; Chen, Marcus Y ; St Hilaire, Cynthia ; Smith, Kevin ; Bagheri, Hadi ; Katz, James D ; Ferreira, Carlos R ; Gahl, William A ; Boehm, Manfred ; Brofferio, Alessandra</creatorcontrib><description>Background:
Arterial calcification due to deficiency of CD73 (ACDC; OMIM 211800) is a rare genetic disease resulting in calcium deposits in arteries and small joints causing claudication, resting pain, severe joint pain, and deformities. Currently, there are no standard treatments for ACDC. Our previous work identified etidronate as a potential targeted ACDC treatment, using in vitro and in vivo disease models with patient-derived cells. In this study, we test the safety and effectiveness of etidronate in attenuating the progression of lower-extremity arterial calcification and vascular blood flow based on the computed tomography (CT) calcium score and ankle–brachial index (ABI).
Methods:
Seven adult patients with a confirmed genetic diagnosis of ACDC were enrolled in an open-label, nonrandomized, single-arm pilot study for etidronate treatment. They took etidronate daily for 14 days every 3 months and were examined at the NIH Clinical Center bi-annually for 3 years. They received a baseline evaluation as well as yearly follow up after treatment. Study visits included imaging studies, exercise tolerance tests with ABIs, clinical blood and urine testing, and full dental exams.
Results:
Etidronate treatment appeared to have slowed the progression of further vascular calcification in lower extremities as measured by CT but did not have an effect in reversing vascular and/or periarticular joint calcifications in our small ACDC cohort.
Conclusions:
Etidronate was found to be safe and well tolerated by our patients and, despite the small sample size, appeared to show an effect in slowing the progression of calcification in our ACDC patient cohort.
(ClinicalTrials.gov Identifier NCT01585402)</description><identifier>ISSN: 1358-863X</identifier><identifier>ISSN: 1477-0377</identifier><identifier>EISSN: 1477-0377</identifier><identifier>DOI: 10.1177/1358863X241235669</identifier><identifier>PMID: 38568107</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>5'-Nucleotidase - deficiency ; 5'-Nucleotidase - genetics ; Adult ; Aged ; Ankle ; Ankle Brachial Index ; Arteries ; Arteriosclerosis ; Arthralgia ; Blood flow ; Bone Density Conservation Agents - adverse effects ; Bone Density Conservation Agents - therapeutic use ; Calcification ; Calcification (ectopic) ; Calcium ; Cardiovascular diseases ; CD73 antigen ; Cell culture ; Computed tomography ; Computed Tomography Angiography ; Disease Progression ; Effectiveness ; Etidronic acid ; Etidronic Acid - adverse effects ; Etidronic Acid - therapeutic use ; Evaluation ; Extremities ; Female ; Genetic disorders ; Genetic Predisposition to Disease ; Genetic screening ; GPI-Linked Proteins - blood ; Health services ; Humans ; In vivo methods and tests ; Lower Extremity - blood supply ; Male ; Middle Aged ; Pain ; Patients ; Peripheral Arterial Disease - diagnosis ; Peripheral Arterial Disease - drug therapy ; Peripheral Arterial Disease - physiopathology ; Pilot Projects ; Regional Blood Flow ; Time Factors ; Treatment Outcome ; Vascular Calcification - diagnostic imaging ; Vascular Calcification - drug therapy</subject><ispartof>Vascular medicine (London, England), 2024-06, Vol.29 (3), p.245-255</ispartof><rights>The Author(s) 2024</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c424t-e10d9481767a5ef2513f26ea38f03b05c21164ca47a2857b699f038ea0ad7d413</citedby><cites>FETCH-LOGICAL-c424t-e10d9481767a5ef2513f26ea38f03b05c21164ca47a2857b699f038ea0ad7d413</cites><orcidid>0000-0002-2098-8883 ; 0000-0002-0352-709X ; 0000-0003-1871-6915</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1358863X241235669$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1358863X241235669$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>230,314,776,780,881,21799,27903,27904,43600,43601</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38568107$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ferrante, Elisa A</creatorcontrib><creatorcontrib>Cudrici, Cornelia D</creatorcontrib><creatorcontrib>Rashidi, Mahmood</creatorcontrib><creatorcontrib>Fu, Yi-Ping</creatorcontrib><creatorcontrib>Huffstutler, Rebecca</creatorcontrib><creatorcontrib>Carney, Katherine</creatorcontrib><creatorcontrib>Chen, Marcus Y</creatorcontrib><creatorcontrib>St Hilaire, Cynthia</creatorcontrib><creatorcontrib>Smith, Kevin</creatorcontrib><creatorcontrib>Bagheri, Hadi</creatorcontrib><creatorcontrib>Katz, James D</creatorcontrib><creatorcontrib>Ferreira, Carlos R</creatorcontrib><creatorcontrib>Gahl, William A</creatorcontrib><creatorcontrib>Boehm, Manfred</creatorcontrib><creatorcontrib>Brofferio, Alessandra</creatorcontrib><title>Pilot study to evaluate the safety and effectiveness of etidronate treatment for arterial calcification due to deficiency of CD73 (ACDC)</title><title>Vascular medicine (London, England)</title><addtitle>Vasc Med</addtitle><description>Background:
Arterial calcification due to deficiency of CD73 (ACDC; OMIM 211800) is a rare genetic disease resulting in calcium deposits in arteries and small joints causing claudication, resting pain, severe joint pain, and deformities. Currently, there are no standard treatments for ACDC. Our previous work identified etidronate as a potential targeted ACDC treatment, using in vitro and in vivo disease models with patient-derived cells. In this study, we test the safety and effectiveness of etidronate in attenuating the progression of lower-extremity arterial calcification and vascular blood flow based on the computed tomography (CT) calcium score and ankle–brachial index (ABI).
Methods:
Seven adult patients with a confirmed genetic diagnosis of ACDC were enrolled in an open-label, nonrandomized, single-arm pilot study for etidronate treatment. They took etidronate daily for 14 days every 3 months and were examined at the NIH Clinical Center bi-annually for 3 years. They received a baseline evaluation as well as yearly follow up after treatment. Study visits included imaging studies, exercise tolerance tests with ABIs, clinical blood and urine testing, and full dental exams.
Results:
Etidronate treatment appeared to have slowed the progression of further vascular calcification in lower extremities as measured by CT but did not have an effect in reversing vascular and/or periarticular joint calcifications in our small ACDC cohort.
Conclusions:
Etidronate was found to be safe and well tolerated by our patients and, despite the small sample size, appeared to show an effect in slowing the progression of calcification in our ACDC patient cohort.
(ClinicalTrials.gov Identifier NCT01585402)</description><subject>5'-Nucleotidase - deficiency</subject><subject>5'-Nucleotidase - genetics</subject><subject>Adult</subject><subject>Aged</subject><subject>Ankle</subject><subject>Ankle Brachial Index</subject><subject>Arteries</subject><subject>Arteriosclerosis</subject><subject>Arthralgia</subject><subject>Blood flow</subject><subject>Bone Density Conservation Agents - adverse effects</subject><subject>Bone Density Conservation Agents - therapeutic use</subject><subject>Calcification</subject><subject>Calcification (ectopic)</subject><subject>Calcium</subject><subject>Cardiovascular diseases</subject><subject>CD73 antigen</subject><subject>Cell culture</subject><subject>Computed tomography</subject><subject>Computed Tomography Angiography</subject><subject>Disease Progression</subject><subject>Effectiveness</subject><subject>Etidronic acid</subject><subject>Etidronic Acid - adverse effects</subject><subject>Etidronic Acid - therapeutic use</subject><subject>Evaluation</subject><subject>Extremities</subject><subject>Female</subject><subject>Genetic disorders</subject><subject>Genetic Predisposition to Disease</subject><subject>Genetic screening</subject><subject>GPI-Linked Proteins - blood</subject><subject>Health services</subject><subject>Humans</subject><subject>In vivo methods and tests</subject><subject>Lower Extremity - blood supply</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pain</subject><subject>Patients</subject><subject>Peripheral Arterial Disease - diagnosis</subject><subject>Peripheral Arterial Disease - drug therapy</subject><subject>Peripheral Arterial Disease - physiopathology</subject><subject>Pilot Projects</subject><subject>Regional Blood Flow</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Vascular Calcification - diagnostic imaging</subject><subject>Vascular Calcification - drug therapy</subject><issn>1358-863X</issn><issn>1477-0377</issn><issn>1477-0377</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc9u1DAQhy0EoqXwAFyQJS7lkOKJE9s5oSqlBakSHEDiFs0649ZVNi62s9K-AY-Nly3lnzjZ8nzz-Tcaxp6DOAHQ-jXI1hglv9QN1LJVqnvADqHRuhJS64flXurVDjhgT1K6EUJo1cFjdiBNqwwIfci-ffRTyDzlZdzyHDhtcFowE8_XxBM6yluO88jJObLZb2imlHhwnLIfY5h_oJEwr2nO3IXIMWaKHiducbLeeYvZh5mPC-38I5UXT7Pd7iT9mZb8-LQ_6189ZY8cTome3Z1H7PP520_9u-ryw8X7_vSysk3d5IpAjF1jQCuNLbm6BelqRSiNE3IlWlsDqMZio7E2rV6prisFQyhw1GMD8oi92Xtvl9WaRltiR5yG2-jXGLdDQD_8WZn99XAVNkPxClMyFMPxnSGGrwulPKx9sjRNOFNY0iCFBNUa1XYFffkXehOWOJf5CqWFkBJAFgr2lI0hpUjuPg2IYbfo4Z9Fl54Xv49x3_FzswU42QMJr-jXt_83fgezI7Fv</recordid><startdate>20240601</startdate><enddate>20240601</enddate><creator>Ferrante, Elisa A</creator><creator>Cudrici, Cornelia D</creator><creator>Rashidi, Mahmood</creator><creator>Fu, Yi-Ping</creator><creator>Huffstutler, Rebecca</creator><creator>Carney, Katherine</creator><creator>Chen, Marcus Y</creator><creator>St Hilaire, Cynthia</creator><creator>Smith, Kevin</creator><creator>Bagheri, Hadi</creator><creator>Katz, James D</creator><creator>Ferreira, Carlos R</creator><creator>Gahl, William A</creator><creator>Boehm, Manfred</creator><creator>Brofferio, Alessandra</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>M7Z</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2098-8883</orcidid><orcidid>https://orcid.org/0000-0002-0352-709X</orcidid><orcidid>https://orcid.org/0000-0003-1871-6915</orcidid></search><sort><creationdate>20240601</creationdate><title>Pilot study to evaluate the safety and effectiveness of etidronate treatment for arterial calcification due to deficiency of CD73 (ACDC)</title><author>Ferrante, Elisa A ; Cudrici, Cornelia D ; Rashidi, Mahmood ; Fu, Yi-Ping ; Huffstutler, Rebecca ; Carney, Katherine ; Chen, Marcus Y ; St Hilaire, Cynthia ; Smith, Kevin ; Bagheri, Hadi ; Katz, James D ; Ferreira, Carlos R ; Gahl, William A ; Boehm, Manfred ; Brofferio, Alessandra</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c424t-e10d9481767a5ef2513f26ea38f03b05c21164ca47a2857b699f038ea0ad7d413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>5'-Nucleotidase - deficiency</topic><topic>5'-Nucleotidase - genetics</topic><topic>Adult</topic><topic>Aged</topic><topic>Ankle</topic><topic>Ankle Brachial Index</topic><topic>Arteries</topic><topic>Arteriosclerosis</topic><topic>Arthralgia</topic><topic>Blood flow</topic><topic>Bone Density Conservation Agents - adverse effects</topic><topic>Bone Density Conservation Agents - therapeutic use</topic><topic>Calcification</topic><topic>Calcification (ectopic)</topic><topic>Calcium</topic><topic>Cardiovascular diseases</topic><topic>CD73 antigen</topic><topic>Cell culture</topic><topic>Computed tomography</topic><topic>Computed Tomography Angiography</topic><topic>Disease Progression</topic><topic>Effectiveness</topic><topic>Etidronic acid</topic><topic>Etidronic Acid - adverse effects</topic><topic>Etidronic Acid - therapeutic use</topic><topic>Evaluation</topic><topic>Extremities</topic><topic>Female</topic><topic>Genetic disorders</topic><topic>Genetic Predisposition to Disease</topic><topic>Genetic screening</topic><topic>GPI-Linked Proteins - blood</topic><topic>Health services</topic><topic>Humans</topic><topic>In vivo methods and tests</topic><topic>Lower Extremity - blood supply</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pain</topic><topic>Patients</topic><topic>Peripheral Arterial Disease - diagnosis</topic><topic>Peripheral Arterial Disease - drug therapy</topic><topic>Peripheral Arterial Disease - physiopathology</topic><topic>Pilot Projects</topic><topic>Regional Blood Flow</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Vascular Calcification - diagnostic imaging</topic><topic>Vascular Calcification - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ferrante, Elisa A</creatorcontrib><creatorcontrib>Cudrici, Cornelia D</creatorcontrib><creatorcontrib>Rashidi, Mahmood</creatorcontrib><creatorcontrib>Fu, Yi-Ping</creatorcontrib><creatorcontrib>Huffstutler, Rebecca</creatorcontrib><creatorcontrib>Carney, Katherine</creatorcontrib><creatorcontrib>Chen, Marcus Y</creatorcontrib><creatorcontrib>St Hilaire, Cynthia</creatorcontrib><creatorcontrib>Smith, Kevin</creatorcontrib><creatorcontrib>Bagheri, Hadi</creatorcontrib><creatorcontrib>Katz, James D</creatorcontrib><creatorcontrib>Ferreira, Carlos R</creatorcontrib><creatorcontrib>Gahl, William A</creatorcontrib><creatorcontrib>Boehm, Manfred</creatorcontrib><creatorcontrib>Brofferio, Alessandra</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biochemistry Abstracts 1</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Vascular medicine (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ferrante, Elisa A</au><au>Cudrici, Cornelia D</au><au>Rashidi, Mahmood</au><au>Fu, Yi-Ping</au><au>Huffstutler, Rebecca</au><au>Carney, Katherine</au><au>Chen, Marcus Y</au><au>St Hilaire, Cynthia</au><au>Smith, Kevin</au><au>Bagheri, Hadi</au><au>Katz, James D</au><au>Ferreira, Carlos R</au><au>Gahl, William A</au><au>Boehm, Manfred</au><au>Brofferio, Alessandra</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pilot study to evaluate the safety and effectiveness of etidronate treatment for arterial calcification due to deficiency of CD73 (ACDC)</atitle><jtitle>Vascular medicine (London, England)</jtitle><addtitle>Vasc Med</addtitle><date>2024-06-01</date><risdate>2024</risdate><volume>29</volume><issue>3</issue><spage>245</spage><epage>255</epage><pages>245-255</pages><issn>1358-863X</issn><issn>1477-0377</issn><eissn>1477-0377</eissn><abstract>Background:
Arterial calcification due to deficiency of CD73 (ACDC; OMIM 211800) is a rare genetic disease resulting in calcium deposits in arteries and small joints causing claudication, resting pain, severe joint pain, and deformities. Currently, there are no standard treatments for ACDC. Our previous work identified etidronate as a potential targeted ACDC treatment, using in vitro and in vivo disease models with patient-derived cells. In this study, we test the safety and effectiveness of etidronate in attenuating the progression of lower-extremity arterial calcification and vascular blood flow based on the computed tomography (CT) calcium score and ankle–brachial index (ABI).
Methods:
Seven adult patients with a confirmed genetic diagnosis of ACDC were enrolled in an open-label, nonrandomized, single-arm pilot study for etidronate treatment. They took etidronate daily for 14 days every 3 months and were examined at the NIH Clinical Center bi-annually for 3 years. They received a baseline evaluation as well as yearly follow up after treatment. Study visits included imaging studies, exercise tolerance tests with ABIs, clinical blood and urine testing, and full dental exams.
Results:
Etidronate treatment appeared to have slowed the progression of further vascular calcification in lower extremities as measured by CT but did not have an effect in reversing vascular and/or periarticular joint calcifications in our small ACDC cohort.
Conclusions:
Etidronate was found to be safe and well tolerated by our patients and, despite the small sample size, appeared to show an effect in slowing the progression of calcification in our ACDC patient cohort.
(ClinicalTrials.gov Identifier NCT01585402)</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>38568107</pmid><doi>10.1177/1358863X241235669</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-2098-8883</orcidid><orcidid>https://orcid.org/0000-0002-0352-709X</orcidid><orcidid>https://orcid.org/0000-0003-1871-6915</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1358-863X |
| ispartof | Vascular medicine (London, England), 2024-06, Vol.29 (3), p.245-255 |
| issn | 1358-863X 1477-0377 1477-0377 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11608424 |
| source | MEDLINE; SAGE Complete A-Z List; Alma/SFX Local Collection |
| subjects | 5'-Nucleotidase - deficiency 5'-Nucleotidase - genetics Adult Aged Ankle Ankle Brachial Index Arteries Arteriosclerosis Arthralgia Blood flow Bone Density Conservation Agents - adverse effects Bone Density Conservation Agents - therapeutic use Calcification Calcification (ectopic) Calcium Cardiovascular diseases CD73 antigen Cell culture Computed tomography Computed Tomography Angiography Disease Progression Effectiveness Etidronic acid Etidronic Acid - adverse effects Etidronic Acid - therapeutic use Evaluation Extremities Female Genetic disorders Genetic Predisposition to Disease Genetic screening GPI-Linked Proteins - blood Health services Humans In vivo methods and tests Lower Extremity - blood supply Male Middle Aged Pain Patients Peripheral Arterial Disease - diagnosis Peripheral Arterial Disease - drug therapy Peripheral Arterial Disease - physiopathology Pilot Projects Regional Blood Flow Time Factors Treatment Outcome Vascular Calcification - diagnostic imaging Vascular Calcification - drug therapy |
| title | Pilot study to evaluate the safety and effectiveness of etidronate treatment for arterial calcification due to deficiency of CD73 (ACDC) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T19%3A15%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pilot%20study%20to%20evaluate%20the%20safety%20and%20effectiveness%20of%20etidronate%20treatment%20for%20arterial%20calcification%20due%20to%20deficiency%20of%20CD73%20(ACDC)&rft.jtitle=Vascular%20medicine%20(London,%20England)&rft.au=Ferrante,%20Elisa%20A&rft.date=2024-06-01&rft.volume=29&rft.issue=3&rft.spage=245&rft.epage=255&rft.pages=245-255&rft.issn=1358-863X&rft.eissn=1477-0377&rft_id=info:doi/10.1177/1358863X241235669&rft_dat=%3Cproquest_pubme%3E3070033113%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3070033113&rft_id=info:pmid/38568107&rft_sage_id=10.1177_1358863X241235669&rfr_iscdi=true |